Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORPIO-HR: S-217622 vs placebo in non-hospitalized adults with COVID-19
jRCT2031220353Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing S-217622 with Placebo (2 arms). Primary endpoint: Time to sustained symptom resolution. Started Dec 2022; status: active, not recruiting.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220353.